The estimated Net Worth of Suma Krishnan is at least $384 Million dollars as of 11 June 2024. Ms Krishnan owns over 50,000 units of Krystal Biotech Inc stock worth over $315,531,813 and over the last 11 years she sold KRYS stock worth over $68,040,471. In addition, she makes $532,269 as Founder and COO & Director at Krystal Biotech Inc.
Ms has made over 30 trades of the Krystal Biotech Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 50,000 units of KRYS stock worth $8,788,000 on 11 June 2024.
The largest trade she's ever made was selling 100,000 units of Krystal Biotech Inc stock on 10 December 2021 worth over $7,050,000. On average, Ms trades about 32,314 units every 100 days since 2014. As of 11 June 2024 she still owns at least 1,587,262 units of Krystal Biotech Inc stock.
You can see the complete history of Ms Krishnan stock trades at the bottom of the page.
Suma M. Krishnan is the Founder, COO & Director at Krystal Biotech Inc.
As the Founder and COO & Director of Krystal Biotech Inc, the total compensation of Ms Krishnan at Krystal Biotech Inc is $532,269. There are 3 executives at Krystal Biotech Inc getting paid more, with Krish S. Krishnan M.B.A., M.S. having the highest compensation of $1,008,932.
Ms Krishnan is 56, she's been the Founder and COO & Director of Krystal Biotech Inc since . There are no older and 10 younger executives at Krystal Biotech Inc.
Suma's mailing address filed with the SEC is C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203.
Over the last 7 years, insiders at Krystal Biotech Inc have traded over $166,816,526 worth of Krystal Biotech Inc stock and bought 536,800 units worth $5,949,380 . The most active insiders traders include Daniel Janney, Dino A Rossi, and Krish S Krishnan. On average, Krystal Biotech Inc executives and independent directors trade stock every 40 days with the average trade being worth of $8,043,043. The most recent stock trade was executed by Suma Krishnan on 11 June 2024, trading 50,000 units of KRYS stock currently worth $8,788,000.
krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)
Krystal Biotech Inc executives and other stock owners filed with the SEC include: